Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 19;10(1):20218.
doi: 10.1038/s41598-020-76995-2.

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Affiliations

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Katarzyna Wolska-Gawron et al. Sci Rep. .

Abstract

Localized scleroderma (LoSc) is a rare disease manifested by an inflammation and sclerosis of the skin. The latest studies focused on glycoprotein Krebs von den Lungen-6, surfactant protein-D, chemokine ligand 18 and dipeptidylpeptidase 4 as potential biomarkers of skin fibrosis in systemic scleroderma. Our study aimed to identify 6 miRNAs with elevated or decreased levels in 38 LoSc patients (31 females, 7 males) compared to healthy volunteers (HVs) and to correlate the selected miRNAs' serum levels with the severity and the clinical symptoms of LoSc and some laboratory parameters with the selected miRNAs' serum levels. The serum levels of miRNAs, i.e. miRNA-181b-5p, miRNA-223-3p, miRNA-21-5p, let 7i-5p, miRNA-29a-3p and miRNA-210-3p were significantly increased in the LoSc patients compared to the HVs. The level of let-7i increase in the female LoSc patients correlated negatively with BSA (r = - 0.355, p = 0.049) and mLoSSI (r = - 0.432, p = 0.015). Moreover, the female patients with inactive LoSc had significantly higher level of let-7i (2.68-fold on average) in comparison to those with active disease (p = 0.045). The exact role of those molecules has not been revealed in LoSc and a long-term longitudinal research is pivotal to confirm their prognostic value.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The strategy of miRNAs selection in our study.
Figure 2
Figure 2
miRNAs’ relative fold change (2−ΔΔCt) in all localized scleroderma patients compared to healthy volunteers (a) and in female localized scleroderma patients compared to healthy volunteers (b). p for Mann–Whitney’s test, LoSc localized scleroderma, IQR interquartile range.
Figure 3
Figure 3
Relative fold change (2−ΔΔCt) of let-7i-5p versus BSA (a) and mLoSSI (b) in female localized scleroderma patients. r Spearman’s correlation coefficient, BSA body surface area, mLoSSI modified Localized Scleroderma Skin Severity Index.
Figure 4
Figure 4
Statistically significant correlations between miRNAs’ relative fold change (2−ΔΔCt) and clinical characteristics of the female localized scleroderma patients. (a) Relative fold change in patients versus healthy volunteers. (b) Relative fold change in patients compared between two groups. p for Mann–Whitney’s test, IQR interquartile range, LoSc localized scleroderma, CRP C-reactive protein, RF rheumatoid factor, EPwS erythematous patches without sclerosis, ADs concurrent autoimmune diseases.
Figure 5
Figure 5
Enrichment analysis. (A) The KEGG pathway analysis of hsa-181b-5p; (B) the KEGG pathway analysis of hsa-miR-223-3p; (C) the KEGG pathway analysis of hsa-210-3p; (D) the KEGG pathway analysis of hsa-let-7i-5p; (E) the KEGG pathway analysis of hasmiR-21-5p; (F) the KEGG pathway analysis of hsa-29a-3p. The enrichment score is expressed as –log (p value).

Similar articles

Cited by

References

    1. Kreuter A, et al. German guidelines for the diagnosis and therapy of localized scleroderma. JDDG J. der Dtsch. Dermatol. Gesellschaft. 2016;14:199–216. doi: 10.1111/ddg.12724. - DOI - PubMed
    1. Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: Current concepts. Clin. Dermatol. 2018;36:475–486. doi: 10.1016/j.clindermatol.2018.04.005. - DOI - PubMed
    1. Knobler R, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. J. Eur. Acad. Dermatol. Venereol. 2017;31:1401–1424. doi: 10.1111/jdv.14458. - DOI - PubMed
    1. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: A proof-of-concept study. Rheumatology (Oxford) 2010;49:373–381. doi: 10.1093/rheumatology/kep361. - DOI - PMC - PubMed
    1. Ruksha TG, Komina AV, Palkina NV. MicroRNA in skin diseases. Eur. J. Dermatol. 2017;27:343–352. doi: 10.1684/ejd.2017.3024. - DOI - PubMed

Publication types